Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ExPEC10V Vaccine in Adults Aged 60 to 85 Years
NCT03819049Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2019
- Primary completion
- Jun 2021
- Modality
- Split/Subunit Vaccines
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of ExPEC10V in extraintestinal pathogenic Escherichia coli infection (7 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Solicited Local (Injection Site) Adverse Events at 14 days, Number of Participants With Solicited Systemic Adverse Events at 14 days and 8 more. Started Jun 2019; status: completed.
02
Drugs
ExPEC10V
03
Conditions
extraintestinal pathogenic Escherichia coli infection
Beyond the preview
Go deeper on NCT03819049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819049.